Prognostic value of CtIP/RBBP8 expression in breast cancer

por Soria-Bretones, Isabel, Sáez, Carmen, Ruíz-Borrego, Manuel, Japón, Miguel A, Huertas, Pablo
Publicado 2013

Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer

por Gasca, Jessica, Flores, Maria Luz, Giráldez, Servando, Ruiz-Borrego, Manuel, Tortolero, María, Romero, Francisco, Japón, Miguel A., Sáez, Carmen
Publicado 2016

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

por Cejuela, Mónica, Gil-Torralvo, Ana, Castilla, M. Ángeles, Domínguez-Cejudo, M. Ángeles, Falcón, Alejandro, Benavent, Marta, Molina-Pinelo, Sonia, Ruiz-Borrego, Manuel, Salvador Bofill, Javier
Publicado 2023

Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study

por Llombart-Cussac, Antonio, Anton-Torres, Antonio, Rojas, Beatriz, Andrés, Raquel, Martinez, Noelia, Rodríguez, César A., Marin, Sara, Puértolas, Teresa, González, Alejandro Falcón, Fernández-Murga, María Leonor, Hagen, Carlos, Ruiz-Borrego, Manuel
Publicado 2023

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

por Martin, Miguel, Brase, Jan C, Calvo, Lourdes, Krappmann, Kristin, Ruiz-Borrego, Manuel, Fisch, Karin, Ruiz, Amparo, Weber, Karsten E, Munarriz, Blanca, Petry, Christoph, Rodriguez, Cesar A, Kronenwett, Ralf, Crespo, Carmen, Alba, Emilio, Carrasco, Eva, Casas, Maribel, Caballero, Rosalia, Rodriguez-Lescure, Alvaro
Publicado 2014

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis

por Pajares, Bella, Pollán, Marina, Martín, Miguel, Mackey, John R, Lluch, Ana, Gavila, Joaquín, Vogel, Charles, Ruiz-Borrego, Manuel, Calvo, Lourdes, Pienkowski, Tadeusz, Rodríguez-Lescure, Álvaro, Seguí, Miguel Angel, Tredan, Olivier, Antón, Antonio, Ramos, Manuel, Cámara, María del Carmen, Rodríguez-Martín, César, Carrasco, Eva, Alba, Emilio
Publicado 2013

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative b...

por Martin, Miguel, Brase, Jan C., Ruiz, Amparo, Prat, Aleix, Kronenwett, Ralf, Calvo, Lourdes, Petry, Christoph, Bernard, Philip S., Ruiz-Borrego, Manuel, Weber, Karsten E., Rodriguez, César A., Alvarez, Isabel M., Segui, Miguel A., Perou, Charles M., Casas, Maribel, Carrasco, Eva, Caballero, Rosalía, Rodriguez-Lescure, Alvaro
Publicado 2016

Role of germline variants in the metastasis of breast carcinomas

por Santonja, Ángela, Moya-García, Aurelio A., Ribelles, Nuria, Jiménez-Rodríguez, Begoña, Pajares, Bella, Fernández-De Sousa, Cristina E., Pérez-Ruiz, Elísabeth, del Monte-Millán, María, Ruiz-Borrego, Manuel, de la Haba, Juan, Sánchez-Rovira, Pedro, Romero, Atocha, González-Neira, Anna, Lluch, Ana, Alba, Emilio
Publicado 2022

Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

por Martín, Miguel, Carrasco, Eva, Rodríguez-Lescure, Álvaro, Andrés, Raquel, Servitja, Sonia, Antón, Antonio, Ruiz-Borrego, Manuel, Bermejo, Begoña, Guerrero, Ángel, Ramos, Manuel, Santaballa, Ana, Muñoz, Montserrat, Cruz, Josefina, Lopez-Tarruella, Sara, Chacón, Jose I., Álvarez, Isabel, Martínez, Purificación, Miralles, Juan J., Polonio, Óscar, Jara, Carlos, Aguiar-Bujanda, David
Publicado 2023

New Insights into the Role of the Immune Microenvironment in Breast Carcinoma

por de la Cruz-Merino, Luis, Barco-Sánchez, Antonio, Henao Carrasco, Fernando, Nogales Fernández, Esteban, Vallejo Benítez, Ana, Brugal Molina, Javier, Martínez Peinado, Antonio, Grueso López, Ana, Ruiz Borrego, Manuel, Codes Manuel de Villena, Manuel, Sánchez-Margalet, Víctor, Nieto-García, Adoración, Alba Conejo, Emilio, Casares Lagar, Noelia, Ibáñez Martínez, José
Publicado 2013

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

por Pérez-García, José Manuel, Vaz Batista, Marta, Cortez, Patricia, Ruiz-Borrego, Manuel, Cejalvo, Juan Miguel, de la Haba-Rodriguez, Juan, Garrigós, Laia, Racca, Fabricio, Servitja, Sonia, Blanch, Salvador, Gion, María, Nave, Monica, Fernández-Abad, María, Martinez-Bueno, Alejandro, Llombart-Cussac, Antonio, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier, Braga, Sofía
Publicado 2022

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

por Asleh, Karama, Lluch, Ana, Goytain, Angela, Barrios, Carlos, Wang, Xue Q., Torrecillas, Laura, Gao, Dongxia, Ruiz-Borrego, Manuel, Leung, Samuel, Bines, José, Guerrero-Zotano, Ángel, García-Sáenz, Jose Ángel, Cejalvo, Juan Miguel, Herranz, Jesus, Torres, Roberto, de la Haba-Rodriguez, Juan, Ayala, Francisco, Gómez, Henry, Rojo, Federico, Nielsen, Torsten O., Martin, Miguel
Publicado 2023

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

por Pascual, Javier, Gil-Gil, Miguel, Proszek, Paula, Zielinski, Christoph, Reay, Alistair, Ruiz-Borrego, Manuel, Cutts, Rosalind, Ciruelos Gil, Eva M., Feber, Andrew, Muñoz-Mateu, Montserrat, Swift, Claire, Bermejo, Begoña, Herranz, Jesus, Margeli Vila, Mireia, Antón, Antonio, Kahan, Zsuzsanna, Csöszi, Tibor, Liu, Yuan, Fernandez-Garcia, Daniel, Garcia-Murillas, Isaac, Hubank, Michael, Turner, Nicholas C., Martín, Miguel
Publicado 2023

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

por Chan, Arlene, Ruiz-Borrego, Manuel, Marx, Gavin, Chien, A. Jo, Rugo, Hope S., Brufsky, Adam, Thirlwell, Michael, Trudeau, Maureen, Bose, Ron, García-Sáenz, José A., Egle, Daniel, Pistilli, Barbara, Wassermann, Johanna, Cheong, Kerry A., Schnappauf, Benjamin, Semsek, Dieter, Singer, Christian F., Foruzan, Navid, DiPrimeo, Daniel, McCulloch, Leanne, Hurvitz, Sara A., Barcenas, Carlos H.
Publicado 2022

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

por Guerrero-Zotano, Ángel, Belli, Stefania, Zielinski, Christoph, Gil-Gil, Miguel, Fernandez-Serra, Antonio, Ruiz-Borrego, Manuel, Ciruelos Gil, Eva Maria, Pascual, Javier, Muñoz-Mateu, Montserrat, Bermejo, Begoña, Margeli Vila, Mireia, Antón, Antonio, Murillo, Laura, Nissenbaum, Bella, Liu, Yuan, Herranz, Jesús, Fernández-García, Daniel, Caballero, Rosalía, López-Guerrero, José Antonio, Bianco, Roberto, Formisano, Luigi, Turner, Nicholas, Martín, Miguel
Publicado 2023

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

por Albanell, Joan, Pérez-García, José Manuel, Gil-Gil, Miguel, Curigliano, Giuseppe, Ruíz-Borrego, Manuel, Comerma, Laura, Gibert, Joan, Bellet, Meritxell, Bermejo, Begoña, Calvo, Lourdes, de la Haba, Juan, Espinosa, Enrique, Minisini, Alessandro Marco, Quiroga, Vanesa, Santaballa Bertran, Ana, Mina, Leonardo, Bellosillo, Beatriz, Rojo, Federico, Menéndez, Silvia, Sampayo-Cordero, Miguel, Popa, Crina, Malfettone, Andrea, Cortés, Javier, Llombart-Cussac, Antonio
Publicado 2023

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIF...

por Di Cosimo, Serena, Pérez-García, José Manuel, Bellet, Meritxell, Dalenc, Florence, Gil Gil, Miguel J, Ruiz Borrego, Manuel, Gavilá, Joaquín, Sampayo-Cordero, Miguel, Aguirre, Elena, Schmid, Peter, Marmé, Frederik, Gligorov, Joseph, Schneeweiss, Andreas, Albanell, Joan, Zamora, Pilar, Wheatley, Duncan, Martínez-De Dueñas, Eduardo, Carañana, Vicente, Amillano, Kepa, Mina, Leonardo, Malfettone, Andrea, Cortés, Javier, Llombart-Cussac, Antonio
Publicado 2022

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

por Martín, Miguel, Prat, Aleix, Rodríguez-Lescure, Álvaro, Caballero, Rosalía, Ebbert, Mark T. W., Munárriz, Blanca, Ruiz-Borrego, Manuel, Bastien, Roy R. L., Crespo, Carmen, Davis, Carole, Rodríguez, César A., López-Vega, José M., Furió, Vicente, García, Ana M., Casas, Maribel, Ellis, Matthew J., Berry, Donald A., Pitcher, Brandelyn N., Harris, Lyndsay, Ruiz, Amparo, Winer, Eric, Hudis, Clifford, Stijleman, Inge J., Tuck, David P., Carrasco, Eva, Perou, Charles M., Bernard, Philip S.
Publicado 2013

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

por Cazet, Aurélie S., Hui, Mun N., Elsworth, Benjamin L., Wu, Sunny Z., Roden, Daniel, Chan, Chia-Ling, Skhinas, Joanna N., Collot, Raphaël, Yang, Jessica, Harvey, Kate, Johan, M. Zahied, Cooper, Caroline, Nair, Radhika, Herrmann, David, McFarland, Andrea, Deng, Niantao, Ruiz-Borrego, Manuel, Rojo, Federico, Trigo, José M., Bezares, Susana, Caballero, Rosalía, Lim, Elgene, Timpson, Paul, O’Toole, Sandra, Watkins, D. Neil, Cox, Thomas R., Samuel, Michael S., Martín, Miguel, Swarbrick, Alexander
Publicado 2018

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

por Bastien, Roy RL, Rodríguez-Lescure, Álvaro, Ebbert, Mark TW, Prat, Aleix, Munárriz, Blanca, Rowe, Leslie, Miller, Patricia, Ruiz-Borrego, Manuel, Anderson, Daniel, Lyons, Bradley, Álvarez, Isabel, Dowell, Tracy, Wall, David, Seguí, Miguel Ángel, Barley, Lee, Boucher, Kenneth M, Alba, Emilio, Pappas, Lisa, Davis, Carole A, Aranda, Ignacio, Fauron, Christiane, Stijleman, Inge J, Palacios, José, Antón, Antonio, Carrasco, Eva, Caballero, Rosalía, Ellis, Matthew J, Nielsen, Torsten O, Perou, Charles M, Astill, Mark, Bernard, Philip S, Martín, Miguel
Publicado 2012